Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease - Full Text View

Purpose

The purpose of this study is to determine the effect of orally given paracetamol on the vascular function and on 24-hour blood pressure in patients with coronary artery disease

Condition	Intervention	Phase
Coronary Arteriosclerosis Endothelial Function	Drug: Paracetamol	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease

Resource links provided by NLM:

MedlinePlus related topics: Coronary Artery Disease

U.S. FDA Resources

Further study details as provided by University of Zurich:

Primary Outcome Measures:

Primary Efficacy endpoint: To investigate the effect of paracetamol on endothelial function as compared to placebo in patients with stable coronary artery disease. [ Time Frame: 2 weeks ]
primary safety endpoint: to evaluate the effect of paracetamol on 24-hour systolic and diastolic blood pressure as compared to placebo in patients with stable coronary artery disease. [ Time Frame: 2 Weeks ]

Secondary Outcome Measures:

To investigate the effect of paracetamol on markers of inflammation and oxidative stress as well as platelet function [ Time Frame: two weeks ]


Enrollment:	37
Study Start Date:	November 2006
Study Completion Date:	January 2010
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Intervention Details:

Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.

Detailed Description:

Patients with chronic pain diseases (e.g. osteoarthritis) are dependent on effective medication. NSAIDs are very effective in lowering pain in these patients. Recently there has aroused major concern with regard to cardiovascular side effects and safety, especially in selective cyclooxygenase-2 inhibitors (coxibs) but also in "regular" NSAIDs.

At the moment, there is a big confusion, whether these drugs still should be used, especially in patients with known coronary artery disease. Physicians now try to switch to high dose paracetamol, despite the weaker efficacy in pain relieve, because this drug is considered generally as not harmful.

As there is very few information on the cardiovascular effect of this drug, we plan to perform this study and investigate the impact of paracetamol on endothelial function, an important cardiovascular surrogate marker, on inflammatory markers and on oxidative stress in patients with coronary artery disease on top of standard medication, including aspirin

Eligibility


Ages Eligible for Study:	30 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age: 30 - 80 years
History of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test)
Stable cardiovascular medication for at least 1 month
Written obtained informed consent

Exclusion Criteria:- myocardial infarction, unstable angina, stroke within 3 months prior to study entry

coronary intervention/revascularisation procedure within 3 months prior to study entry
Left ventricular ejection fraction <50%
Other analgesics (Platelet inhibition therapy with Aspirin 100mg/d will be continued)
Long acting nitrates
Smoking
Chronic heart failure (> NYHA II)
Ventricular tachyarrhythmias
Renal failure (serum creatinine >200umol)
Liver disease (ALT or AST >100 IU), especially acute hepatitis
Hyperbilirubinemia
Alcohol abuse
Oral Anticoagulation
Concomitant therapy with Phenobarbital, Phenytoin, Carbamazepin, Isonicotinic Acid, Chloramphenicol Chlorzoxazone, Zidovudine, Salicylamide
Insulin-dependent diabetes mellitus
Drug abuse
Anemia (Hb<10 g/dl)
Known allergies on Paracetamol
Pregnancy
Malignancy (unless healed or remission > 5 years)
Symptomatic hypotension, hypertension >160/100 mmHg
Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)
Participation in another study within the last month

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00534651

Locations


Switzerland
University Hospital
Zurich, Switzerland, 8091

Sponsors and Collaborators

University of Zurich

Investigators


Principal Investigator:	Frank Ruschitzka, MD	University of Zurich

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sudano I, Flammer AJ, Périat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Lüscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010 Nov 2;122(18):1789-96. doi: 10.1161/CIRCULATIONAHA.110.956490. Epub 2010 Oct 18.


Responsible Party:	Prof Frank Ruschitzka, Cardiovascular Center, Cardiology University Hospital Zurich
ClinicalTrials.gov Identifier:	NCT00534651 History of Changes
Other Study ID Numbers:	EK1265
Study First Received:	September 24, 2007
Last Updated:	March 15, 2010

Additional relevant MeSH terms:


Coronary Artery Disease Myocardial Ischemia Coronary Disease Arteriosclerosis Heart Diseases Cardiovascular Diseases Arterial Occlusive Diseases Vascular Diseases	Acetaminophen Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antipyretics

ClinicalTrials.gov processed this record on September 19, 2017